Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 03, 2025 10:00 ET | Source: Boundless Bio, Inc.

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...
December 12, 2024 16:01 ET | Source: Boundless Bio, Inc.

Boundless Bio Announces Pipeline and Leadership Updates

Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway...
November 25, 2024 07:00 ET | Source: Boundless Bio, Inc.

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...
November 07, 2024 16:01 ET | Source: Boundless Bio, Inc.

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash position of $167 million, with operating...
November 05, 2024 07:00 ET | Source: Boundless Bio, Inc.

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...
October 14, 2024 08:00 ET | Source: Boundless Bio, Inc.

Boundless Bio Announces Departure of Chief Financial Officer

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...
September 11, 2024 07:00 ET | Source: Boundless Bio, Inc.

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

SAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies...
August 12, 2024 16:01 ET | Source: Boundless Bio, Inc.

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now expected in the second half of 2025 BBI-825...